questionsmedicales.fr
Composés chimiques organiques
Amidines
Guanidines
Biguanides
Biguanides : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Diabète de type 2
Glycémie
HbA1c
Résistance à l'insuline
Test de tolérance au glucose
HOMA-IR
Diabète
Symptômes
Hyperglycémie
Biguanides
Glycémie
HbA1c
Symptômes
5
Biguanides
Effets secondaires
Gastro-intestinal
Hypoglycémie
Symptômes
Diabète
Acidose lactique
Symptômes
Biguanides
Diabète
Complications
Symptômes
Biguanides
Appétit
Perte de poids
Prévention
5
Prévention
Diabète de type 2
Mode de vie sain
Facteurs de risque
Obésité
Diabète
Poids corporel
Résistance à l'insuline
Diabète
Activité physique
Prévention
Diabète
Contrôles médicaux
Diabète
Prévention
Traitements
5
Biguanides
Insuline
Glucose
Metformine
Biguanides
Diabète de type 2
Biguanides
Diabète de type 2
Traitement
Metformine
Dosage
Diabète
Biguanides
Antidiabétiques
Traitement combiné
Complications
5
Complications
Diabète
Maladies cardiovasculaires
Prévention
Complications
Diabète
Neuropathie diabétique
Symptômes
Diabète
Néphropathie
Diabète
Complications
Examens médicaux
Complications
Diabète
Facteurs de risque
5
Facteurs de risque
Diabète
Obésité
Hérédité
Diabète
Facteurs de risque
Tabagisme
Diabète
Facteurs de risque
Alimentation
Diabète
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Biguanides : Questions médicales les plus fréquentes",
"headline": "Biguanides : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Biguanides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-17",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Biguanides"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Guanidines",
"url": "https://questionsmedicales.fr/mesh/D006146",
"about": {
"@type": "MedicalCondition",
"name": "Guanidines",
"code": {
"@type": "MedicalCode",
"code": "D006146",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Buformine",
"alternateName": "Buformin",
"url": "https://questionsmedicales.fr/mesh/D002026",
"about": {
"@type": "MedicalCondition",
"name": "Buformine",
"code": {
"@type": "MedicalCode",
"code": "D002026",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.075"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chlorhexidine",
"alternateName": "Chlorhexidine",
"url": "https://questionsmedicales.fr/mesh/D002710",
"about": {
"@type": "MedicalCondition",
"name": "Chlorhexidine",
"code": {
"@type": "MedicalCode",
"code": "D002710",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Metformine",
"alternateName": "Metformin",
"url": "https://questionsmedicales.fr/mesh/D008687",
"about": {
"@type": "MedicalCondition",
"name": "Metformine",
"code": {
"@type": "MedicalCode",
"code": "D008687",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phenformine",
"alternateName": "Phenformin",
"url": "https://questionsmedicales.fr/mesh/D010629",
"about": {
"@type": "MedicalCondition",
"name": "Phenformine",
"code": {
"@type": "MedicalCode",
"code": "D010629",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Proguanil",
"alternateName": "Proguanil",
"url": "https://questionsmedicales.fr/mesh/D002727",
"about": {
"@type": "MedicalCondition",
"name": "Proguanil",
"code": {
"@type": "MedicalCode",
"code": "D002727",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D02.078.370.141.710"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Biguanides",
"alternateName": "Biguanides",
"code": {
"@type": "MedicalCode",
"code": "D001645",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Liam Good",
"url": "https://questionsmedicales.fr/author/Liam%20Good",
"affiliation": {
"@type": "Organization",
"name": "Pathobiology and Population Sciences, The Royal Veterinary College, London, England."
}
},
{
"@type": "Person",
"name": "Alan A Rogers",
"url": "https://questionsmedicales.fr/author/Alan%20A%20Rogers",
"affiliation": {
"@type": "Organization",
"name": "Flintshire, North Wales, UK."
}
},
{
"@type": "Person",
"name": "Manuel D Gahete",
"url": "https://questionsmedicales.fr/author/Manuel%20D%20Gahete",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
},
{
"@type": "Person",
"name": "Justo P Castaño",
"url": "https://questionsmedicales.fr/author/Justo%20P%20Casta%C3%B1o",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
},
{
"@type": "Person",
"name": "Raúl M Luque",
"url": "https://questionsmedicales.fr/author/Ra%C3%BAl%20M%20Luque",
"affiliation": {
"@type": "Organization",
"name": "Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Lipidomics of cyclophosphamide 4-hydroxylation in patients receiving post-transplant cyclophosphamide.",
"datePublished": "2022-09-24",
"url": "https://questionsmedicales.fr/article/36088654",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/cts.13404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35608373",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/09612033221103205"
}
},
{
"@type": "ScholarlyArticle",
"name": "Revisited Cyclophosphamide in the Treatment of Lupus Nephritis.",
"datePublished": "2022-05-26",
"url": "https://questionsmedicales.fr/article/35707391",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/8345737"
}
},
{
"@type": "ScholarlyArticle",
"name": "Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.",
"datePublished": "2024-10-22",
"url": "https://questionsmedicales.fr/article/39437137",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/EVIDoa2300354"
}
},
{
"@type": "ScholarlyArticle",
"name": "Protective Effects of Antioxidants on Cyclophosphamide-Induced Ovarian Toxicity.",
"datePublished": "2022-06-13",
"url": "https://questionsmedicales.fr/article/35696235",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/bio.2021.0159"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés chimiques organiques",
"item": "https://questionsmedicales.fr/mesh/D009930"
},
{
"@type": "ListItem",
"position": 3,
"name": "Amidines",
"item": "https://questionsmedicales.fr/mesh/D000578"
},
{
"@type": "ListItem",
"position": 4,
"name": "Guanidines",
"item": "https://questionsmedicales.fr/mesh/D006146"
},
{
"@type": "ListItem",
"position": 5,
"name": "Biguanides",
"item": "https://questionsmedicales.fr/mesh/D001645"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Biguanides - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Biguanides",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Biguanides",
"description": "Comment diagnostiquer le diabète de type 2 ?\nQuels tests sont utilisés pour évaluer la résistance à l'insuline ?\nQuels symptômes indiquent un diabète non contrôlé ?\nComment évaluer l'efficacité des biguanides ?\nQuels sont les critères de diagnostic du diabète ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Biguanides",
"description": "Quels sont les effets secondaires des biguanides ?\nComment reconnaître une hypoglycémie ?\nQuels symptômes peuvent indiquer une acidose lactique ?\nQuels signes indiquent une mauvaise gestion du diabète ?\nComment les biguanides affectent-ils l'appétit ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Biguanides",
"description": "Comment prévenir le diabète de type 2 ?\nQuels facteurs de risque sont modifiables ?\nComment le poids corporel influence-t-il le diabète ?\nQuel rôle joue l'activité physique dans la prévention ?\nLes contrôles médicaux réguliers sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Biguanides",
"description": "Comment les biguanides agissent-ils ?\nQuels sont les principaux biguanides utilisés ?\nQuand commencer un traitement par biguanides ?\nQuels sont les dosages habituels de metformine ?\nLes biguanides peuvent-ils être combinés avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Biguanides",
"description": "Quelles sont les complications du diabète mal contrôlé ?\nComment prévenir les complications liées au diabète ?\nQuels sont les signes d'une neuropathie diabétique ?\nComment le diabète affecte-t-il la santé rénale ?\nQuels examens sont nécessaires pour surveiller les complications ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Biguanides",
"description": "Quels sont les principaux facteurs de risque du diabète ?\nL'hérédité joue-t-elle un rôle dans le diabète ?\nComment le stress influence-t-il le diabète ?\nLe tabagisme est-il un facteur de risque ?\nQuel impact a l'alimentation sur le risque de diabète ?",
"url": "https://questionsmedicales.fr/mesh/D001645?mesh_terms=Cyclophosphamide#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer le diabète de type 2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de glycémie, comme la glycémie à jeun ou l'HbA1c."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la résistance à l'insuline ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le test de tolérance au glucose et l'indice HOMA-IR sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un diabète non contrôlé ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent soif excessive, urination fréquente et fatigue persistante."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des biguanides ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction de la glycémie et l'amélioration de l'HbA1c."
}
},
{
"@type": "Question",
"name": "Quels sont les critères de diagnostic du diabète ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent une glycémie à jeun ≥ 7 mmol/L ou HbA1c ≥ 6,5%."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des biguanides ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une hypoglycémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent tremblements, sueurs, confusion et palpitations."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une acidose lactique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue extrême, douleurs musculaires et respiration rapide."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une mauvaise gestion du diabète ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des infections fréquentes, des plaies qui guérissent lentement et des troubles de la vision."
}
},
{
"@type": "Question",
"name": "Comment les biguanides affectent-ils l'appétit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biguanides peuvent réduire l'appétit, contribuant ainsi à la perte de poids chez certains patients."
}
},
{
"@type": "Question",
"name": "Comment prévenir le diabète de type 2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice régulier, aide à prévenir le diabète."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont modifiables ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'obésité, le manque d'activité physique et une alimentation déséquilibrée sont modifiables."
}
},
{
"@type": "Question",
"name": "Comment le poids corporel influence-t-il le diabète ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un excès de poids augmente la résistance à l'insuline, augmentant le risque de diabète."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'activité physique dans la prévention ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'activité physique régulière améliore la sensibilité à l'insuline et aide à contrôler le poids."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des contrôles réguliers aident à détecter précocement le diabète et à gérer les risques."
}
},
{
"@type": "Question",
"name": "Comment les biguanides agissent-ils ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils diminuent la production de glucose par le foie et augmentent la sensibilité à l'insuline."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux biguanides utilisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La metformine est le biguanide le plus couramment prescrit pour le diabète de type 2."
}
},
{
"@type": "Question",
"name": "Quand commencer un traitement par biguanides ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement commence généralement après un diagnostic de diabète de type 2 et un échec des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les dosages habituels de metformine ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les doses varient de 500 mg à 2000 mg par jour, selon la tolérance et la réponse du patient."
}
},
{
"@type": "Question",
"name": "Les biguanides peuvent-ils être combinés avec d'autres médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être combinés avec d'autres antidiabétiques pour un meilleur contrôle glycémique."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications du diabète mal contrôlé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des maladies cardiovasculaires, des neuropathies et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées au diabète ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un bon contrôle glycémique et des examens réguliers aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une neuropathie diabétique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des picotements, des engourdissements et des douleurs dans les membres."
}
},
{
"@type": "Question",
"name": "Comment le diabète affecte-t-il la santé rénale ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diabète peut entraîner une néphropathie, affectant la fonction rénale et provoquant des complications."
}
},
{
"@type": "Question",
"name": "Quels examens sont nécessaires pour surveiller les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction rénale, des pieds et des yeux sont essentiels."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque du diabète ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, l'âge avancé, l'hérédité et le mode de vie sédentaire."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle dans le diabète ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un antécédent familial de diabète augmente le risque de développer la maladie."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il le diabète ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut affecter la glycémie et la gestion du diabète, augmentant le risque de complications."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de diabète et de complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Quel impact a l'alimentation sur le risque de diabète ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en sucres et en graisses saturées augmente le risque de diabète."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Pathobiology and Population Sciences, The Royal Veterinary College, London, England.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Flintshire, North Wales, UK.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
3 publications dans cette catégorie
Affiliations :
Maimonides Institute for Biomedical Research of Cordoba, Córdoba, Spain.
Department of Cell Biology, Physiology, and Immunology, University of Córdoba, Córdoba, Spain.
Reina Sofia University Hospital, Córdoba, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición, Córdoba, Spain.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
University of Colorado Hospital, Aurora, CO, USA.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Institut de Chimie de Nice UMR7272, Parc Valrose, Université Côte d'Azur, Nice, France.
Department of Chemical and Biochemical Sciences, Mohammed VI Polytechnic University (UM6P), Ben Guerir, Morocco.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Antibiotics, Biocides, Residues and Resistance Unit, Fougères Laboratory, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Fougères, France.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
R&D-Safety Science Research, Kao Corporation.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
R&D-Safety Science Research, Kao Corporation.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Molecular Chirality Research Center, Chiba University.
Plant Molecular Science Center, Chiba University.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Medical Mycology Research Center.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Département de Biochimie et Médecine Moléculaire, and CRCHUM-Faculté de Médecine, Université de Montréal, Montreal, QC, Canada. g.ferbeyre@umontreal.ca.
Publications dans "Biguanides" :
2 publications dans cette catégorie
Affiliations :
Département de Chimie-Faculté des Arts et des Sciences, Université de Montréal, 2900 Edouard Montpetit, Succursale Centre-Ville, CP 6128, Montreal, QC, H3C3J7, Canada. ar.schmitzer@umontreal.ca.
Publications dans "Biguanides" :
Biomarker-guided dosing may improve the efficacy and toxicity of cyclophosphamide (CY); however, clinical studies evaluating their association with the area under the plasma concentration-time curve (...
There is a paradigm shift in the induction therapy for proliferative lupus nephritis (LN). Apart from cyclophosphamide (CYC), mycophenolate mofetil and calcineurin inhibitors have emerged as an altern...
We aimed to compare the cost-effectiveness analysis (CEA) per year, adverse events and renal damage at 24 months between CYC and non-CYC agents (calcineurin inhibitors or mycophenolate) as induction t...
This was a retrospective and non-controlled study involving biopsy-proven proliferative LN patients (class III or IV with or without V) in the clinic registry from 2017 to 2019. Their medical records ...
There were a total of 95 inductions with CYC and 27 with non-CYC in 94 LN patients. There was no significant difference in the total mean cost per patient/year between CYC (MYR 18460.26 ± 6500.76) com...
Lupus nephritis (LN) is the most common serious complication of systemic lupus erythematosus (SLE). The pathogenesis of LN is complex, and the majority causes of LN are the renal deposition of circula...
Cyclophosphamide and infliximab are recommended as induction therapies for severe Behçet's syndrome. Whether infliximab is safer and more effective than cyclophosphamide in treating severe Behçet's sy...
In this phase 2, Bayesian, multicenter randomized controlled trial, we assigned patients fulfilling the International Study Group's criteria for Behçet's syndrome who had major vascular or central ner...
Between May 2018 and April 2021, 52 patients with severe Behçet's syndrome (n=37 [71%] with vascular Behçet's syndrome and n=15 [29%] with neuro-Behçet's syndrome) were randomly assigned to receive ei...
Among patients with severe Behçet's syndrome, induction therapy with infliximab had a superior complete response rate at 22 weeks and fewer adverse events than induction with cyclophosphamide. (Funded...
The most common limitation of anticancer chemotherapy is the injury to normal cells. Cyclophosphamide, which is one of the most widely used alkylating agents, can cause premature ovarian insufficiency...
Cyclophosphamide is an alkylating agent used in routine pulmonary practice, particularly in the management of connectivitis-related diffuse interstitial lung disease. Common side effects are gastroint...
A 78-year-old female patient treated for NSIP-OP in the context of an anti-synthetase syndrome was treated with Cyclophosphamide 15mg/kg. Twenty-four hours after the end of the infusion, she was diagn...
Hyponatremia induced by low-dose Cyclophosphamide is a rare but serious adverse effect that requires special attention....
Oligoasthenozoospermia is becoming a serious problem, but effective prevention or treatment is lacking. Hyperoside, one of the main active ingredients in traditional Chinese medicine, may be effective...
Results of randomized clinical trials have demonstrated rituximab's noninferiority to cyclophosphamide as induction therapy for antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV), ...
To compare the effectiveness of rituximab and cyclophosphamide in inducing GPA remission in a large population of unselected patients....
This comparative effectiveness study used multicenter target trial emulation observational data from 32 French hospitals in the French Vasculitis Study Group Registry. Groups were determined according...
At least 1 infusion of rituximab or cyclophosphamide for induction therapy between April 1, 2008, and April 1, 2018....
The primary outcome was remission rate at month 6 (±2 months), with remission defined as a Birmingham Vasculitis Activity Score (BVAS) of 0 and prednisone dose of 10 mg/d or less. The BVAS is a valida...
Among 194 patients with GPA included in the analysis (mean [SD] age, 54 [15] years; 110 men [56.7%]), 165 (85.1%) had a new diagnosis, and 147 of 182 with data available (80.8%) had proteinase 3-ANCA ...
In this comparativeness effectiveness study using clinical data, rituximab induction therapy for GPA was more frequently associated with remission than cyclophosphamide. These results inform clinical ...
Cytomegalovirus reactivation (CMV-R) is a significant complication of allogeneic hematopoietic stem cell transplantation (allo-HCT), especially in human leukocyte antigen-haploidentical transplantatio...
We retrospectively analyzed 52 patients seropositive for CMV who underwent haplo-HCT with PTCy at our institution between January 2015 and June 2021 and compared patients who received LTV prophylaxis ...
The 100-day cumulative CMV-R incidence was lower in the LTV group than in the control group (17.2% vs 81.8%, p < 0.001). Multivariate analysis revealed that prophylactic LTV reduced the 100-day cumula...
Prophylactic LTV effectively prevents CMV-R in patients undergoing haplo-HCT for PTCy....
"Secondary exposure to anticancer drugs" refers to exposure to anticancer drugs after chemotherapy via the patient's urine and other excretions. The necessity of countermeasures against secondary expo...
The study population included eight patients with malignant lymphoma who received CHOP therapy between May and December 2021. The amount of CPA in their underwear (namely, cotton short-sleeved shirts)...
CPA was detected in the underwear of all the patients, with levels ranging between 7.38 and 160.77 ng/cm...
These results suggested that patients' sweat, as well as urine, is a potential route for exposure to anticancer drugs. Whether visibly contaminated or not, the clothing and linen worn directly by pati...